# PETACC-8 miR-31-3p and miR-31-5p Ancillary Study

> **NCT03362684** · PHASE3 · COMPLETED · sponsor: **IntegraGen SA** · enrollment: 1808 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** FOLFOX

## Key facts

- **NCT ID:** NCT03362684
- **Lead sponsor:** IntegraGen SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2009-11
- **Final completion:** 2016-06-30
- **Target enrollment:** 1808 (ACTUAL)
- **Last updated:** 2017-12-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03362684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03362684, "PETACC-8 miR-31-3p and miR-31-5p Ancillary Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03362684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*